Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246

Xiaolei Zhou(Karolinska Institutet), Galina Selivanova(Karolinska Institutet)
British Journal of Cancer
September 22, 2022
10.1038/s41416-022-01971-8
Cited by 23

Related Papers

Inhibition of p53 inhibitors: progress, challenges and perspectives
|Journal of Molecular Cell Biology|2019|137
Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2
|Cell Cycle|2011|118
The type 2 cytokine Fc–IL-4 revitalizes exhausted CD8+ T cells against cancer
|Nature|2024|118